

**THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION**

ACTION REQUEST

Subject: Project Agreements with the University of Michigan

Action Requested: Authorization to enter into or amend Agreements

Preamble:

Statutory conflicts of interest situations were identified by the Office of Research and Sponsored Projects while reviewing Proposal Approval Forms that then triggered a review by the Medical School Conflict of Interest Board and/or the OVPR Conflict of Interest Committee. Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved at time of award.

These proposed project (e.g., research, sponsored activity, and/or subcontract) agreements (“Agreement”) and/or amendments to Agreements (“Amendments”) fall under the State of Michigan Conflict of Interest Statute because University of Michigan (“University”) employees have activities, relationships, or interests in the companies as described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents (“Regents”) of the University and approved in advance by a 2/3 vote.

Agreement Terms:

The terms of the Agreements and/or Amendments conform to University policy. The funding support will not exceed the amount reported in Attachment A for each Agreement and/or Amendment. Since projects are often amended, these Agreements and/or Amendments include provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreements and/or Amendments will provide support of investigator’s effort to use their expertise and University laboratories, as well as other University resources, to execute the projects as reported in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Medical School Conflict of Interest Board and/or the OVPR Conflict of Interest Committee. In light of this disclosure and our finding that the Agreements and Amendments were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into or amending the Agreements referenced in Attachment A.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Arthur Lupia', with a stylized flourish at the end.

Arthur Lupia
Vice President for Research and Innovation

November 2025

Attachment A

Project #1

**Subcontract Agreement between the University and And Battery Aero Inc.
Reviewed by OVPR Conflict of Interest Committee**

Project Information

Title: HERALD - High Energy Renewable Afx
eLectroDes - Phase II

U-M Project ID: 26-PAF02826

Direct Sponsor: And Battery Aero Inc.

Prime Sponsor: Energy, Department of-Subcontracts

Principal Investigator/Department: Venkat Viswanathan, Aerospace Engineering

Project Duration: Two (2) Years

Funding Support: \$750,000

Purpose: The purpose of this project is the continued chemistry level optimization of HERALD cathode and electrolyte, to fully characterize a HERALD multi-layer pouch cell through accelerated life testing, and develop a framework for the reliability of HERALD cells in real applications.

University Employee; University Title; Relationship with And Battery Aero Inc.

- Venkat Viswanathan; Associate Professor, Aerospace Engineering; Partial Owner

Project #2

**Subcontract Agreement between the University and Arborsense, Inc.
Reviewed by the Medical School Conflict of Interest Board and the OVPR Conflict of Interest Committee**

Project Information

Title: A wearable alcohol monitor to detect low-level drinking

U-M Project ID: 25-PAF06753

Direct Sponsor: Arborsense, Inc.

Prime Sponsor: Health and Human Services, Department of-National Institutes of Health-Subcontracts

Principal Investigator/Department: Xudong Fan, Biomedical Engineering

Project Duration: Six (6) Months

Funding Support: \$61,510

Purpose: The purpose of this project is to develop a wearable alcohol monitor to detect low-level drinking.

University Employee; University Title; Relationship with Arborsense, Inc.

- Xudong Fan; Professor, Biomedical Engineering; Partial Owner
- Zhaohui Zhong; Associate Professor, Electrical Engineering and Computer Science – Electrical and Computer Engineering (EECS – ECE) Division; Partial Owner
- Mark Ilgen; Professor, Psychiatry; Partial Owner

Project #3

Amendment to Other Sponsored Activity Agreement between the University and ASKO Pharma, LLC Reviewed by OVPR Conflict of Interest Committee	
<u>Project Information</u>	
Title: ASKO Pharma General Service Agreement - Amendment 1	U-M Project ID: 26-PAF03178
Direct Sponsor: ASKO Pharma, LLC	
Principal Investigator/Department: Anna Schwendeman, Pharmaceutical Sciences	
Current Project Duration: Two (2) Years Additional Time: Two (2) Years	Current Funding Support: \$200,000 Additional Funding Support: \$200,000
Purpose: The purpose of this amendment is to add time and funds so Drs. Anna Schwendeman and Steven Schwendeman may continue to provide four categories of services (analytical characterization, in vivo sample analysis, large scale in vitro sample analysis, and formulation of drug products) in their labs.	
<u>University Employee; University Title; Relationship with ASKO Pharma, LLC</u> • Vishalakshi Krishnan; Associate Director, Center For Research on Complex Generics; Partial Owner • Steven Schwendeman; Professor, Pharmaceutical Sciences; Partial Owner • Anna Schwendeman; Professor, Pharmaceutical Sciences; Partial Owner	

Project #4

Research Agreement between the University and Courage Therapeutics, Inc. Reviewed by OVPR Conflict of Interest Committee	
<u>Project Information</u>	
Title: Preclinical development and characterization of Courage melanocortin peptides	U-M Project ID: 26-PAF03367
Direct Sponsor: Courage Therapeutics, Inc.	
Principal Investigator/Department: Roger Cone, Life Sciences Institute	
Project Duration: Two (2) Years	Funding Support: \$2,469,935
Purpose: The purpose of this project is to characterize melanocortin peptides, as directed by Courage Therapeutics, Inc., with the goal of identifying compounds that may advance to one or more FDA Investigational New Drug applications in the fields of syndromic obesity, dietary obesity, and/or other eating disorders, and any metabolic or behavioral diseases resulting from these disorders.	
<u>University Employee; University Title; Relationship with Courage Therapeutics, Inc.</u> • Roger Cone; Professor, Molecular and Integrative Physiology, and Director of the Life Sciences Institute; Partial Owner	

Project #5

Subcontract Agreement between the University and EVOQ Therapeutics, Inc. Reviewed by OVPR Conflict of Interest Committee	
<u>Project Information</u>	
Title: NanoDiscs for Immune Modulation in Celiac Disease	U-M Project ID: 25-PAF01123
Direct Sponsor: EVOQ Therapeutics, Inc.	Prime Sponsor: Health and Human Services, Department of-National Institutes of Health-Subcontracts
Principal Investigator/Department: James Moon, Pharmaceutial Sciences	
Project Duration: Two (2) Years	Funding Support: \$416,692
Purpose: The purpose of this project is to exploit Tregs to modulate the immune response in Celiac Disease.	
<u>University Employee; University Title; Relationship with EVOQ Therapeutics, Inc.</u> • Anna Schwendeman; Professor, Pharmaceutical Sciences; Partial Owner • James Moon; Professor, Pharmaceutical Sciences; Partial Owner	

Project #6

Subcontract Agreement between the University and HTIC, Inc. Reviewed by Medical School Conflict of Interest Board	
<u>Project Information</u>	
Title: Controlling NETosis to Treat Diabetic Wound (DFU)	U-M Project ID: 24-PAF06588
Direct Sponsor: HTIC, Inc.	Prime Sponsor: Health and Human Services, Department of-National Institutes of Health-Subcontracts
Principal Investigator/Department: Yongqing Li, MM GSA - Acute Care Surgery	
Project Duration: One (1) Year	Funding Support: \$39,000
Purpose: The purpose of this Phase I STTR project is to assess the safety, biocompatibility and efficacy of hCitH3-mAb as a topical therapy for treatment of diabetic wounds.	
<u>University Employee; University Title; Relationship with HTIC, Inc.</u> • Yongqing Li; Associate Professor, Surgery; Partial Owner	

Project #7

Subcontract Agreement between the University and Lumanos Inc. Reviewed by Medical School Conflict of Interest Board	
<u>Project Information</u>	
Title: Myocardial Ischemic Reperfusion Injury Protection thru Human Platelet 12-Lipoxygenase Inhibition	U-M Project ID: 26-PAF01535
Direct Sponsor: Lumanos Inc.	Prime Sponsor: Health and Human Services, Department of-National Institutes of Health-Subcontracts
Principal Investigator/Department: Michael Holinstat, MM Pharmacology	
Project Duration: One (1) Year	Funding Support: \$142,393
Purpose: The purpose of this project is to assess PK/PD for Slug-001 compared to ML355, and to assess myocardial ischemic reperfusion injury (MIRI) protection with Slug-001.	
<u>University Employee; University Title; Relationship with Lumanos Inc.</u> Michael Holinstat; Professor, Pharmacology; Partial Owner	

Project #8

Subcontract Agreement between the University and Lumanos Inc. Reviewed by Medical School Conflict of Interest Board	
<u>Project Information</u>	
Title: Myocardial Ischemic Reperfusion Injury Protection thru Human Platelet 12-Lipoxygenase Inhibition	U-M Project ID: 26-PAF02623
Direct Sponsor: Lumanos Inc.	Prime Sponsor: Health and Human Services, Department of-National Institutes of Health-Subcontracts
Principal Investigator/Department: Michael Holinstat, MM Pharmacology	
Project Duration Three (3) Years	Funding Support: \$1,264,328
Purpose: The purpose of this project is for Dr. Michael Holinstat to oversee all studies related to this project conducted at the University of Michigan. Specifically, the 12-LOX inhibitory compounds will be tested in mice and rats. PK will be conducted in mice and rats. In vivo animal studies conducted in mice will include the 1) laser-induced cremaster arteriole thrombosis assay and the 2) carotid artery thrombosis assay. Additionally, mouse and/or rat studies will be conducted in the lab of Dr. Ahmed Abdel-latif for myocardial ischemic reperfusion injury (MIRI) and the overseen by Dr. Holinstat. All studies will be analyzed in the Holinstat lab. For MIRI studies, both prevention and intervention studies will be conducted on the compounds of interest.	
<u>University Employee; University Title; Relationship with Lumanos Inc.</u> Michael Holinstat; Professor, Pharmacology; Partial Owner	

Project #9

Research Agreement between the University and Osteo Science Foundation Reviewed by OVPR Conflict of Interest Committee	
<u>Project Information</u>	
Title: Osteo Science Mentorship Award - Klahs	U-M Project ID: 26-PAF02262
Direct Sponsor: Osteo Science Foundation	
Principal Investigator/Department: Hsiao Hsin Sung, Maxillofacial Surgery	
Project Duration: One (1) Year	Funding Support: \$5,000
Purpose: The purpose of project is to provide essential safety and feasibility data, supporting the development of innovative regenerative dental solutions that may expand OSA therapy access for an at-risk, underserved population.	
<u>University Employee; University Title; Relationship with Osteo Science Foundation</u> • Sean Edwards; Clinical Professor, Oral And Maxillofacial Surgery; Board of Directors Member	

Project #10

Research Agreement between the University and Osteo Science Foundation Reviewed by OVPR Conflict of Interest Committee	
<u>Project Information</u>	
Title: Biomarkers and Bone Healing in Two Mandibular Implant for Overdenture	U-M Project ID: 26-PAF02318
Direct Sponsor: Osteo Science Foundation	
Principal Investigator/Department: Hsiao Hsin Sung, Maxillofacial Surgery	
Project Duration: One (1) Year	Funding Support: \$5,000
Purpose: The purposes of this project is to characterize the biological and structural changes occurring in peri-implant tissues following two-implant overdenture therapy, with a focus on dynamic markers of tissue stability that reflect both the outcomes and sustainability of regenerative processes after functional loading.	
<u>University Employee; University Title; Relationship with Osteo Science Foundation</u> • Sean Edwards; Clinical Professor, Oral And Maxillofacial Surgery; Board of Directors Member	

Project #11

Subcontract Agreement between the University and Prevada Medical, Inc. Reviewed by Medical School Conflict of Interest Board	
<u>Project Information</u>	
Title: VAP Prevention Mouthguard	U-M Project ID: 26-PAF01027
Direct Sponsor: Prevada Medical, Inc.	Prime Sponsor: Health and Human Services, Department of-National Institutes of Health-Subcontracts
Principal Investigator/Department: J VanEpps, Emergency Medicine Research	
Project Duration: Three (3) Years	Funding Support: \$838,993
Purpose: The purpose of this project is to examine the ability of an absorptive mouth piece with and without an antimicrobial agent (two generally regarded as safe food additives: alpha-terpineol and cinnamaldehyde) to decrease subglottic secretion accumulation and favorably modulate the oral microbiome in patients undergoing mechanical ventilation.	
<u>University Employee; University Title; Relationship with Prevada Medical, Inc.</u> Kevin Ward; Professor, Emergency Medicine; Partial Owner	

Project #12

Subcontract Agreement between the University and Propel Aero, Inc. Reviewed by OVPR Conflict of Interest Committee	
<u>Project Information</u>	
Title: High Energy Reloadable Sodium-Air Redox Engine & Fuel Cell System – Phase II	U-M Project ID: 26-PAF02951
Direct Sponsor: Propel Aero, Inc.	Prime Sponsor: Energy, Department of-Subcontracts
Principal Investigator/Department: Venkat Viswanathan, Aerospace Engineering	
Project Duration: Two (2) Years	Funding Support: \$375,000
Purpose: The purpose of this project is to improve the sodium-air component and validation to achieve system-level energy density (>1000 Wh/kg), rate (>300 mA/cm ²), and lifetime (>100 cycles) and development of balance of plant components for the 1 kWh system.	
<u>University Employee; University Title; Relationship with Propel Aero, Inc.</u> Venkat Viswanathan; Associate Professor, Aerospace Engineering; Partial Owner	

Project #13

**Other Sponsored Activity Agreement between the University and RUA Diagnostics Inc.
Reviewed by Medical School Conflict of Interest Board and OVPR Conflict of Interest Committee**

Project Information

Title: RUA Diagnostics	U-M Project ID: 26-PAF00821
Direct Sponsor: RUA Diagnostics Inc.	
Principal Investigator/Department: Kevin Ward, Emergency Medicine UM Adult	
Project Duration: Two (2) Years	Funding Support: \$41,510
Purpose: The purpose of this activity is to conduct gas chromatography of exhaled breath in patients with hypoxic respiratory failure and in healthy controls.	
<u>University Employee; University Title; Relationship with RUA Diagnostics Inc.</u> • Xudong Fan; Professor, Biomedical Engineering; Partial Owner • Kevin Ward; Professor, Emergency Medicine; Partial Owner	

Project #14

**Subcontract Agreement between the University and Tulip Make Me Move Desk, LLC
Reviewed by Medical School Conflict of Interest Board**

Project Information

Title: SBIR Phase II AO Pongmala: In-Home Multifunctional Standing and Stepping Rehabilitation Device for People with Parkinson's disease	U-M Project ID: 26-PAF00588
Direct Sponsor: Tulip Make Me Move Desk, LLC	Prime Sponsor: Health and Human Services, Department of-National Institutes of Health-Subcontracts
Principal Investigator/Department: Fay Pongmala, Radiology	
Project Duration: Three (3) Years	Funding Support: \$1,498,137
Purpose: The purpose of this project is a 12-week randomized controlled, single blinded clinical trial of in-home promotion of low-intensity physical activity while decreasing sedentary behavior using a Multifunctional Rehabilitation Standing and Stepping Device in persons with Parkinson's Disease and Postural Instability and Gait Difficulty features.	
<u>University Employee; University Title; Relationship with Tulip Make Me Move Desk, LLC</u> • Nicolaas Bohnen; Professor, Radiology; Partial Owner	

Project #15

**Subcontract Agreement between the University and Ulendo Technologies, Inc.
Reviewed by OVPR Conflict of Interest Committee**

Project Information

Title: Ulendo SC: Physics-Based Scan Sequence Optimization for Residual Stress and Distortion Reduction in Metal Additive Manufacturing

U-M Project ID: 25-PAF09396

Direct Sponsor: Ulendo Technologies, Inc.

Prime Sponsor: National Science Foundation-Subcontracts

Principal Investigator/Department: Chinedum Okwudire, Mechanical Engineering

Project Duration: Two (2) Years

Funding Support: \$100,000

Purpose: The purpose of this project is to develop a scalable prototype of a software tool that uses physics-based scan sequence optimization to reduce residual stress and distortion in parts produced using laser powder bed fusion (LPBF) metal additive manufacturing.

University Employee; University Title; Relationship with Ulendo Technologies, Inc.

- Chinedum Okwudire; Professor, Mechanical Engineering; Partial Owner